Therefore, to address the threshold that shifts the IFN milieu from a protective to detrimental state will be imperative in identifying markers that allow for appropriate therapeutic administration of IFN or JAK inhibitors to selected patients with COVID-19 (58, 59). The gene discussed is IFNA1; the disease is COVID-19.